EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells

Oncotarget

Volumn 7, Issue 14, 2016, Pages 18050-18064

  Zou, Peng ^a,b   Xia, Yiqun ^b   Chen, Weiqian ^b   Chen, Xi ^b   Ying, Shilong ^b   Feng, Zhiguo ^b   Chen, Tongke ^b   Ye, Qingqing ^b   Wang, Zhe ^b   Qiu, Chenyu ^b   Yang, Shulin ^a   Liang, Guang ^b  

^a NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

EF24; ER stress; Gastric cancer; Reactive oxygen species; Thioredoxin reductase 1

Indexed keywords

3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; FLUOROURACIL; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE 1; 3,5-BIS(2-FLUOROBENZYLIDENE)PIPERIDIN-4-ONE; BENZYLIDENE DERIVATIVE; PIPERIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL LEVEL; CHEMOSENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; FEMALE; GASTRIC CANCER CELL LINE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; STOMACH CANCER; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZYLIDENE COMPOUNDS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PIPERIDONES; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; THIOREDOXIN REDUCTASE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975518639     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7633     Document Type: Article

References (49)

1. Kingston DG. Modern natural products drug discovery and its relevance to biodiversity conservation. Journal of natural products. 2011; 74:496-511
2. Koehn FE and Carter GT. The evolving role of natural products in drug discovery. Nature reviews Drug discovery. 2005; 4:206-220
3. Newman DJ and Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of natural products. 2012; 75:311-335
4. James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, Griffin-Teal N, Thomas A, Greaves P, Cai H, Patel SR, Morgan B, Dennison A, Metcalfe M, Garcea G, Lloyd DM, Berry DP, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer letters. 2015; 364:135-141
5. Soetikno V, Sari FR, Lakshmanan AP, Arumugam S, Harima M, Suzuki K, Kawachi H and Watanabe K. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Molecular nutrition & food research. 2013; 57:1649-1659
6. Prasad S and Tyagi AK. Curcumin and its analogues:a potential natural compound against HIV infection and AIDS. Food & function. 2015; 6:3412-3419
7. Liang G, Li X, Chen L, Yang S, Wu X, Studer E, Gurley E, Hylemon PB, Ye F, Li Y and Zhou H. Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorganic & medicinal chemistry letters. 2008; 18:1525-1529
8. Zou P, Zhang J, Xia Y, Kanchana K, Guo G, Chen W, Huang Y, Wang Z, Yang S and Liang G. ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer. Oncotarget. 2015; 6:5860-5876. doi:10.18632/oncotarget.3333
9. Shen T, Jiang T, Long M, Chen J, Ren DM, Wong PK, Chapman E, Zhou B and Zhang DD. A Curcumin Derivative That Inhibits Vinyl Carbamate-Induced Lung Carcinogenesis via Activation of the Nrf2 Protective Response. Antioxidants & redox signaling. 2015; 23:651-664
10. Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW and Anant S. Diphenyl difluoroketone:a curcumin derivative with potent in vivo anticancer activity. Cancer research. 2008; 68:1962-1969
11. Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J and Liu L. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressordependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology. 2013; 57:1847-1857
12. Yang CH, Yue J, Sims M and Pfeffer LM. The curcumin analog EF24 targets NF-kappaB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS one. 2013; 8:e71130
13. Liu H, Liang Y, Wang L, Tian L, Song R, Han T, Pan S and Liu L. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PloS one. 2012; 7:e48075
14. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E and Giannakakou P. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle. 2008; 7:2409-2417
15. Thomas SL, Zhao J, Li Z, Lou B, Du Y, Purcell J, Snyder JP, Khuri FR, Liotta D and Fu H. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochemical pharmacology. 2010; 80:1309-1316
16. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K and Kuppusamy P. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. The Journal of biological chemistry. 2007; 282:28609-28618
17. Go YM and Jones DP. Thiol/disulfide redox states in signaling and sensing. Critical reviews in biochemistry and molecular biology. 2013; 48:173-181
18. Rigobello MP and Bindoli A. Mitochondrial thioredoxin reductase purification, inhibitor studies, and role in cell signaling. Methods in enzymology. 2010; 474:109-122
19. Li C, Peng Y, Mao B and Qian K. Thioredoxin reductase:a novel, independent prognostic marker in patients with hepatocellular carcinoma. Oncotarget. 2015; 6:17792-17804. doi:10.18632/oncotarget.3785
20. Esen H, Erdi F, Kaya B, Feyzioglu B, Keskin F and Demir LS. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades. Journal of neurooncology. 2015; 121:451-458
21. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L and Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free radical biology & medicine. 2009; 47:1661-1671
22. Yoo MH, Xu XM, Carlson BA, Gladyshev VN and Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. The Journal of biological chemistry. 2006; 281:13005-13008
23. Fan C, Chen J, Wang Y, Wong YS, Zhang Y, Zheng W, Cao W and Chen T. Selenocystine potentiates cancer cell apoptosis induced by 5-fluorouracil by triggering reactive oxygen species-mediated DNA damage and inactivation of the ERK pathway. Free radical biology & medicine. 2013; 65:305-316
24. Tobe R, Yoo MH, Fradejas N, Carlson BA, Calvo S, Gladyshev VN and Hatfield DL. Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism. The Biochemical journal. 2012; 445:423-430
25. Zhang B, Duan D, Ge C, Yao J, Liu Y, Li X and Fang J. Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent. Journal of medicinal chemistry. 2015; 58:1795-1805
26. Cai W, Zhang L, Song Y, Wang B, Zhang B, Cui X, Hu G, Liu Y, Wu J and Fang J. Small molecule inhibitors of mammalian thioredoxin reductase. Free radical biology & medicine. 2012; 52:257-265
27. Kim B, Kim HS, Jung EJ, Lee JY, B KT, Lim JM and Song YS. Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. Molecular carcinogenesis. 2015
28. Wang L, Song R, Shen Y, Sun Y, Gu Y, Shu Y and Xu Q. Targeting sarcoplasmic/endoplasmic reticulum Ca(2)+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Molecular cancer therapeutics. 2011; 10:461-471
29. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL and Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes & development. 1998; 12:982-995
30. Duan D, Zhang B, Yao J, Liu Y and Fang J. Shikonin targets cytosolic thioredoxin reductase to induce ROSmediated apoptosis in human promyelocytic leukemia HL-60 cells. Free radical biology & medicine. 2014; 70:182-193
31. Liu Y, Duan D, Yao J, Zhang B, Peng S, Ma H, Song Y and Fang J. Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase. Journal of medicinal chemistry. 2014; 57:5203-5211
32. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL and Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011; 475:231-234
33. Zou P, Chen M, Ji J, Chen W, Chen X, Ying S, Zhang J, Zhang Z, Liu Z, Yang S and Liang G. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. Oncotarget. 2015; 6:36505-36521. doi:10.18632/oncotarget.5364
34. Mustacich D and Powis G. Thioredoxin reductase. The Biochemical journal. 2000; 346 Pt 1:1-8
35. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer research. 2014; 74:2520-2532
36. Gan FF, Kaminska KK, Yang H, Liew CY, Leow PC, So CL, Tu LN, Roy A, Yap CW, Kang TS, Chui WK and Chew EH. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity. Antioxidants & redox signaling. 2013; 19:1149-1165
37. Li Y, Zhang LP, Dai F, Yan WJ, Wang HB, Tu ZS and Zhou B. Hexamethoxylated Monocarbonyl Analogues of Curcumin Cause G2/M Cell Cycle Arrest in NCI-H460 Cells via Michael Acceptor-Dependent Redox Intervention. Journal of agricultural and food chemistry. 2015; 63:7731-7742
38. Du Y, Zhang H, Lu J and Holmgren A. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. The Journal of biological chemistry. 2012; 287:38210-38219
39. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ and et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993; 71:3813-3818
40. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group. Journal of clinical oncology. 2006; 24:4991-4997
41. Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, Dai G, Xu J, Liu Y, Fan N, Shu Y, Ba Y, Ma D, Qin S, Zheng L, Chen W, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric cancer. 2016; 19:234-44
42. Urig S and Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Seminars in cancer biology. 2006; 16:452-465
43. Tian C, Gao P, Zheng Y, Yue W, Wang X, Jin H and Chen Q. Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death. Cell research. 2008; 18:458-471
44. Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Brustle A, Molyneux SD, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer cell. 2015; 27:211-222
45. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, Gotoh T, Akira S, Bouillet P and Strasser A. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007; 129:1337-1349
46. Joo JH, Liao G, Collins JB, Grissom SF and Jetten AM. Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer research. 2007; 67:7929-7936
47. Zhang XY, Yang SM, Zhang HP, Yang Y, Sun SB, Chang JP, Tao XC, Yang TY, Liu C and Yang YM. Endoplasmic reticulum stress mediates the arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. The international journal of biochemistry & cell biology. 2015; 68:158-165
48. Cao A, Li Q, Yin P, Dong Y, Shi H, Wang L, Ji G, Xie J and Wu D. Curcumin induces apoptosis in human gastric carcinoma AGS cells and colon carcinoma HT-29 cells through mitochondrial dysfunction and endoplasmic reticulum stress. Apoptosis :an international journal on programmed cell death. 2013; 18:1391-1402
49. Ouyang X, Zhou S, Su CT, Ge Z, Li R and Kwoh CK. CovalentDock:automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. Journal of computational chemistry. 2013; 34:326-336